Pfizer to showcase cancer drug data at ESMO Congress 2025

BERLIN - Pfizer Inc. (NYSE:PFE), a prominent player in the pharmaceuticals industry with a market capitalization of $137 billion and annual revenue exceeding $63 billion, will present data from more than 45 research abstracts at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin from October 17-21, according to a press release statement.Want deeper insights into Pfizer’s financial health and growth potential? InvestingPro offers exclusive analysis and 10 key investment tips for PFE.

The pharmaceutical company’s presentations will include 11 oral presentations and five late-breaking sessions covering its oncology portfolio across various tumor types. With a robust gross profit margin of 74%, Pfizer maintains strong financial resources for its research initiatives.

A key highlight will be a Presidential Symposium featuring results from the Phase 3 EV-303 trial evaluating PADCEV (enfortumab vedotin-ejfv) plus KEYTRUDA (pembrolizumab) in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.

Other significant presentations include final overall survival results from the Phase 3 EMBARK trial studying XTANDI (enzalutamide) in non-metastatic hormone-sensitive prostate cancer, and updated survival data from the Phase 2 PHAROS study of BRAFTOVI (encorafenib) plus MEKTOVI (binimetinib) in patients with BRAF V600E-mutant metastatic non-small cell lung cancer.

"At ESMO, Pfizer is demonstrating how earlier interventions with our innovative medicines have the potential to deliver greater impact to even more patients," said Jeff Legos, Chief Oncology Officer at Pfizer, in the release.

The company will also present data on vepdegestrant for breast cancer and ponsegromab for cancer-associated cachexia.

PADCEV is being developed in collaboration with Astellas, while XTANDI is jointly developed and commercialized by Pfizer and Astellas in the United States. The PHAROS trial is conducted with support from Pierre Fabre.

In other recent news, Pfizer has announced a significant acquisition in the obesity treatment space, acquiring Metsera for $7.3 billion. This deal includes an upfront valuation of $4.9 billion and contingent value rights that could add up to $22.50 per share, representing a 42% premium over Metsera’s previous closing price. Analysts from BMO Capital have reiterated an Outperform rating on Pfizer, with a price target of $30, highlighting the acquisition as a strategic move into the obesity metabolic space after previous challenges. Bernstein analysts also maintained a Market Perform rating for Pfizer, echoing a $30 price target following the acquisition.

Additionally, the Trump administration is considering launching a website, potentially named "TrumpRx," to facilitate discounted prescription drug purchases. Meanwhile, a CDC panel has voted to end the universal recommendation for Covid vaccinations, shifting the decision to a personalized approach between patients and healthcare providers. These developments reflect Pfizer’s ongoing strategic maneuvers and the broader healthcare landscape’s evolving dynamics.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.